source
- Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglu…BioSpace · 6d ago↗ source
- Gilead signs $1.9 billion deal with Vir Biotechnology to license dual-masked T-cell engagers for oncologyGilead Sciences announced a licensing agreement with Vir Biotechnology to access Vir's dual-masked PRO-XTEN T-cell engager platform for oncology. Under the deal, Vir will discover, design and opti…